We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
(-4.8%)
Cap. Flow
+$505M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$83.5M |
| 2 |
S&P Global
SPGI
|
+$73.5M |
| 3 |
Tesla
TSLA
|
+$55.8M |
| 4 |
Microsoft
MSFT
|
+$45.9M |
| 5 |
Amazon
AMZN
|
+$27.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$88.8M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$74.7M |
| 3 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$31.7M |
| 4 |
Abbott
ABT
|
+$25.5M |
| 5 |
Exelon
EXC
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 13.53% |
| 3 | Healthcare | 13.01% |
| 4 | Consumer Discretionary | 11.66% |
| 5 | Industrials | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Tenaya Therapeutics
TNYA
$163M
| $269K | ﹤0.01% |
22,798
+12,646
| +125% | +$153K |
|
2677
Tilly's
TLYS
$128M
| $268K | ﹤0.01% |
28,655
-3,359
| -10% | -$41.4K |
|
2678
iRadimed
IRMD
$1.18B
| $266K | ﹤0.01% |
5,925
+747
| +14% | +$34.5K |
|
2679
Atlanticus Holdings
ATLC
$1.52B
| $260K | ﹤0.01% |
5,025
+1,645
| +49% | +$98.9K |
|
2680
Atomera
ATOM
$214M
| $260K | ﹤0.01% |
19,922
+2,260
| +13% | +$33.8K |
|
2681
Blue Ridge Bankshares
BRBS
$332M
| $260K | ﹤0.01% |
17,123
+408
| +2% | +$6.83K |
|
|
ZY
2682
DELISTED
Zymergen Inc. Common Stock
ZY
| $260K | ﹤0.01% |
90,086
+3,902
| +5% | +$16.6K |
|
2683
South Plains Financial
SPFI
$841M
| $258K | ﹤0.01% |
9,698
-999
| -9% | -$28.3K |
|
|
RUBY
2684
DELISTED
Rubius Therapeutics, Inc
RUBY
| $258K | ﹤0.01% |
46,907
-1,114
| -2% | -$7.08K |
|
|
DZSI
2685
DELISTED
DZS Inc. Common Stock
DZSI
| $257K | ﹤0.01% |
18,535
+2,196
| +13% | +$31.8K |
|
|
FYBR
2686
DELISTED
Frontier Communications
FYBR
| $256K | ﹤0.01% |
9,251
| – | – |
|
2687
Greenlight Captial
GLRE
$506M
| $256K | ﹤0.01% |
36,222
-3,684
| -9% | -$26.8K |
|
2688
AerSale
ASLE
$279M
| $255K | ﹤0.01% |
+16,218
| New | +$249K |
|
2689
N-able
NABL
$940M
| $254K | ﹤0.01% |
27,906
-11,801
| -30% | -$124K |
|
|
CURO
2690
DELISTED
CURO Group Holdings Corp.
CURO
| $254K | ﹤0.01% |
19,450
+2,350
| +14% | +$32.4K |
|
2691
Procept Biorobotics
PRCT
$1.17B
| $253K | ﹤0.01% |
+7,226
| New | +$174K |
|
2692
Vroom Inc
VRM
$48.2M
| $253K | ﹤0.01% |
1,187
-270
| -19% | -$128K |
|
|
VIEW
2693
DELISTED
View, Inc. Class A Common Stock
VIEW
| $253K | ﹤0.01% |
2,287
-353
| -13% | -$53.4K |
|
2694
Preformed Line Products
PLPC
$2.28B
| $252K | ﹤0.01% |
3,971
-362
| -8% | -$21.7K |
|
2695
FS KKR Capital
FSK
$3.44B
| $251K | ﹤0.01% |
11,011
-1,261
| -10% | -$27.9K |
|
2696
Immunovant
IMVT
$8.25B
| $251K | ﹤0.01% |
45,464
-25
| -0.1% | -$156 |
|
2697
Pure Cycle
PCYO
$261M
| $251K | ﹤0.01% |
20,868
+234
| +1% | +$2.9K |
|
2698
Immunic
IMUX
$195M
| $250K | ﹤0.01% |
2,212
+518
| +31% | +$60K |
|
|
CMBM
2699
DELISTED
Cambium Networks
CMBM
| $249K | ﹤0.01% |
10,553
+2,532
| +32% | +$61.3K |
|
|
ESPR
2700
DELISTED
Esperion Therapeutics
ESPR
| $249K | ﹤0.01% |
53,717
+22,584
| +73% | +$96.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
- RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
- RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
- RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
- RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
- RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.